Thrombophilia and risk of venous thrombosis in patients with cancer

Thrombosis Research

Volumn 120, Issue SUPPL. 2, 2007, Pages

  Decousus, Hervé ^a   Moulin, Nathalie ^a   Quenet, Sara ^a   Bost, Vincent ^a   Rivron Guillot, Karine ^a   Laporte, Silvy ^a   Mismetti, Patrick ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Cancer; Central venous catheter; Factor V Leiden; Thrombophilia; Thrombosis

Indexed keywords

ASPARAGINASE; BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN DERIVATIVE; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; RALOXIFENE; TAMOXIFEN; THALIDOMIDE;

ACTIVATED PROTEIN C RESISTANCE; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER; CENTRAL VENOUS CATHETERIZATION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; GENE MUTATION; GENETICS; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCREENING; THROMBOCYTOSIS; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ANTIBODIES, ANTIPHOSPHOLIPID; FACTOR V; HUMANS; HYPERHOMOCYSTEINEMIA; MUTATION; NEOPLASMS; PROTHROMBIN; RISK; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 36049014970     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(07)70130-5     Document Type: Article

References (73)

1. Samama M., Dahl O., Quinlan D., Mismetti P., and Rosencher N. Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica 88 (2003) 1410-1421
2. Geerts W., Pineo G., Heit J., Bergqvist D., Lassen M., Colwell C., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 338S-400S
3. Agnelli G., and Verso M. Thrombosis and cancer: clinical relevance of a dangerous liaison. Haematologica 90 (2005) 155-156
4. Prandoni P., Lensing A., Piccioli A., Bernardi E., Simioni P., Girolami B., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 (2002) 3484-3488
5. Levitan N., Dowlati A., Remick S., Tahsildar H., Sivinski L., Beyth R., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78 (1999) 285-291
6. Sorensen H., Mellemkjaer L., Olsen J., and Baron J. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343 (2000) 1846-1850
7. Prandoni P., Falanga A., and Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 6 (2005) 401-410
8. Nicolaides A., Breddin H., Carpenter P., Coccheri S., Conard J., De Stefano V., et al., for The European Genetics Foundation, The Cardiovascular Disease Educational and Research Trust, The International Union of Angiology, The Mediterranean League on Thromboembolism. Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol 24 (2005) 1-26
9. Bertina R., Koeleman B., Koster T., Rosendaal F., Dirven R., de Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
10. Kyrle P., and Eichinger S. Deep vein thrombosis. Lancet 365 (2005) 1163-1174
11. Rosendaal F., Koster T., Vandenbroucke J., and Reitsma P. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85 (1995) 1504-1508
12. Poort S., Rosendaal F., Reitsma P., and Bertina R. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
13. Otterson G., Monahan B., Harold N., Steinberg S., Frame J., and Kaye F. Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am J Med 101 (1996) 406-412
14. Rees D., Grimwade D., Langabeer S., Burnett A., and Goldstone A. Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia. MRC Adult Leukaemia Working Party. Br J Haematol 96 (1997) 490-492
15. Sifontes M., Nuss R., Hunger S., Wilimas J., Jacobson L., and Manco-Johnson M. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 96 (1997) 484-489
16. Haim N., Lanr N., Hoffman R., Haim A., Tsalik M., and Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 110 (2001) 91-96
17. Pihusch R., Danzl G., Scholz M., Harich D., Pihusch M., Lohse P., et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 94 (2002) 3120-3126
18. Ravin A., Edwards R., Krohn M., Kelley J., Chistopherson W., and Roberts J. The factor V Leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients. Obstet Gynecol 100 (2002) 1285-1289
19. Ramacciotti E., Wolosker N., Puech-Leao P., Zeratti E., Gussin P., del Giglio A., et al. Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res 109 (2003) 171-174
20. Kennedy M., Andreescu A., Greenblatt M., Jiang H., Thomas C., Chassereau L., et al. Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. Br J Haematol 128 (2005) 386-388
21. Blom J., Doggen C., Osanto S., and Rosendaal F. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 (2005) 715-722
22. Eroglu A., Ulu A., Cam R., Kurtman C., and Akar N. Prevalence of Factor V 1691 G A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. J Thromb Thrombolysis 23 (2007) 31-34
23. Klerk C., Smorenburg S., and Buller H. Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Arch Intern Med 163 (2003) 1913-1921
24. McGee D., and Gould M. Preventing complications of central venous catheterization. N Engl J Med 348 (2003) 1123-1133
25. Dentali F., Gianni M., and Ageno W. Should common inherited thrombophilic abnormalities be tested in cancer patient with wentral venous catheter. J Thromb Haemost 5 Suppl 2 (2007) P-S-564
26. Riordan M., and Weiden P. Factor V Leiden mutation does not account for central venous catheter-related thrombosis. Am J Hematol 58 (1998) 150-152
27. Ratcliffe M., Broadfoot C., Davidson M., Kelly K., and Greaves M. Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease. Clin Lab Haematol 21 (1999) 353-357
28. Fijnheer R., Paijmans B., Verdonck L., Nieuwenhuis H., Roest M., and Dekker A. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 118 (2002) 267-270
29. Mandala M., Curigliano G., Bucciarelli P., Ferretti G., Mannucci P., Colleoni M., et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 15 (2004) 590-593
30. van Rooden C., Rosendaal F., Meinders A., van Oostayen J., van der Meer F., and Huisman M. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 89 (2004) 201-206
31. Tesselaar M., Ouwerkerk J., Nooy M., Rosendaal F., and Osanto S. Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 40 (2004) 2253-2259
32. Mitchell L., Andrew M., Hanna K., Abshire T., Halton J., Anderson R., et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 97 (2003) 508-516
33. Nowak-Gottl U., Wermes C., Junker R., Koch H., Schobess R., Fleischhack G., et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 93 (1999) 1595-1599
34. Wermes C., von Depka Prondzinski M., Lichtinghagen R., Barthels M., Welte K., and Sykora K.-W. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 158 Suppl 3 (1999) S143-S146
35. Knofler R., Siegert E., Lauterbach I., Taut-Sach H., Siegert G., Gehrisch S., et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy impact of central venous lines. Eur J Pediatr 158 Suppl 3 (1999) S147-S150
36. Mauz-Korholz C., Junker R., Gobel U., and Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and -97 protocols). Thromb Haemost 83 (2000) 840-843
37. Deitcher S., and Gomes M. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 101 (2004) 439-449
38. Duggan C., Marriott K., Edwards R., and Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 21 (2003) 3588-3593
39. Abramson N., Costantino J., Garber J., Berliner N., Wickerham D., and Wolmark N. Effect of Factor V Leiden and prothrombin G20210 →A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst 98 (2006) 904-910
40. Heit J. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3 (2005) 1611-1617
41. de Visser M., Rosendaal F., and Bertina R. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 93 (1999) 1271-1276
42. Rodeghiero F., and Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 130 (1999) 643-650
43. Green D., Maliekel K., Sushko E., Akhtar R., and Soff G. Activated-protein-C resistance in cancer patients. Haemostasis 27 (1997) 112-118
44. De Lucia D., De Vita F., Orditura M., Renis V., Belli A., Conte M., et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C. Tumori 83 (1997) 948-952
45. Paspatis G., Sfyridaki A., Papanikolaou N., Triantafyllou K., Livadiotaki A., Kapsoritakis A., et al. Resistance to activated protein C, factor V leiden and the prothrombin G20210Avariant in patients with colorectal cancer. Pathophysiol Haemost Thromb 32 (2002) 2-7
46. Zangari M., Saghafifar F., Anaissie E., Badros A., Desikan R., Fassas A., et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13 (2002) 187-192
47. Nijziel M., van Oerle R., Christella M., Thomassen L., van Pampus E., Hamulyak K., et al. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol 120 (2003) 117-122
48. Elice F., Fink L., Tricot G., Barlogie B., and Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134 (2006) 399-405
49. Hugo J., and Jeanet D. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 4 (2006) 11
50. Samonakis D., Koutroubakis I., Sfiridaki A., Malliaraki N., Antoniou P., Romanos J., et al. Hypercoagulable states in patients with hepatocellular carcinoma. Dig Dis Sci 49 (2004) 854-858
51. Sciacca F., Ciusani E., Silvani A., Corsini E., Frigerio S., Parati E., et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 10 (2004) 1312-1317
52. Ruud E., Holmstrom H., Brosstad F., and Wesenberg F. Children with acute lymphoblastic leukaemia have high plasma levels of total homocysteine at time of diagnosis. Scand J Clin Lab Invest 66 (2006) 67-78
53. Ely S. Potential risk of a common hereditary thrombophilia and adjuvant chemotherapy for low-stage breast cancer. J Clin Oncol 23 (2005) 4242-4243
54. Gómez-Puerta J., Cervera R., Espinosa G., Aguiló S., Bucciarelli S., Ramos-Casals M., et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 35 (2006) 322-332
55. Yoon K., Wong A., Shakespeare T., and Sivalingam P. High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 12 (2003) 112-116
56. Zuckerman E., Toubi E., Golan T., Rosenvald-Zuckerman T., Sabo E., Shmuel Z., et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 72 (1995) 447-451
57. Miesbach W., Scharrer I., and Asherson R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol 25 (2006) 840-844
58. Rogers II J., Murgo A., Fontana J., and Raich P. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 6 (1988) 276-281
59. Cushman M., Costantino J., Bovill E., Wickerham D., Buckley L., Roberts J., et al. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol 120 (2003) 109-116
60. Kraaijenhagen R., in't Anker P., Koopman M., Reitsma P., Prin M., van den Ende A., et al. High plasma concentration of factors VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 83 (2000) 5-9
61. Zecchina G., Ghio P., Bosio S., Cravino M., Camaschella C., and Scagliotti G. Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. Clin Lung Cancer 8 (2007) 264-267
62. Wehmeir A., Daum I., Jamin H., and Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 63 (1991) 101-106
63. Leone G., Sica S., Chiusolo P., Teofili L., and de Stefano V. Blood cell diseases and thrombosis. Haematologica 86 (2001) 1236-1244
64. Baron J., Gridley G., Weiderpass E., Nyren O., and Linet M. Venous thromboembolism and cancer. Lancet 351 (1998) 1077-1080
65. Harmanci O., Ersoy O., Gurgey A., Buyukasik, Gedikoglu G., Balkanci F., et al. The etiologic distribution of thrombophilic factors in chronic portal vein thrombosis. J Clin Gastroenterol 41 (2007) 521-527
66. Weijl N., Rutten M., Zwinderman A., Keizer H., Nooy M., Rosendaal F., et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 18 (2000) 2169-2178
67. Morgan T., Krumholz H., Lifton R., and Spertus J. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 297 (2007) 1551-1561
68. Rickles F., and Levine M. Epidemiology of thrombosis in cancer. Acta Haematologica 106 (2001) 6-12
69. Chew H., Wun T., Harvey D., Zhou H., and White R. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 25 (2007) 70-76
70. Wu O., Robertson L., Twaddle S., Lowe G., Clark P., Greaves M., et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessement of Thrombophilia Screening (TREATS) study. Health Technol Assess 10 (2006) 1110
71. Ferretti G., Bria E., Felici A., Carlini P., Giannarelli D., Ciccarese M., et al. Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?. Ann Oncol 17 (2006) 528-529
72. Vairaktaris E., Yapijakis C., Wiltfang J., Ries J., Vylliotis A., Derka S., et al. Are factor V and prothrombin mutations associated with increased risk of oral cancer?. Anticancer Res 25 (2005) 2561-2565
73. Battistelli S., Stefanoni M., Genovese A., Vittoria A., Cappelli R., and Roviello F. Prevalence of factor V Leiden and prothrombin G20210A in patients with gastric cancer. World J Gastroenterol 12 (2006) 4179-4180